Soligenix, Inc.

Name: Soligenix, Inc. standardized financial statements, quarterly
Creator: Listed

SNGXNasdaqCIK 812796HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$0, Q4 FY2024

Operating income−$2.1m, Q2 FY2026

Net income−$2.0m, Q2 FY2026

Soligenix, Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$k	130	245	117	2.3	0.0	0.0	not reported	not reported	not reported	not reported	not reported	not reported
Cost of revenue	$k	110	222	117	2.3	0.0	0.0	not reported	not reported	not reported	not reported	not reported	not reported
Gross profit	$k	20.0	23.3	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Research and development	$k	826	778	1,095	501	969	2,659	1,942	1,677	1,584	2,283	1,782	974
Operating income	$k	(1,779)	(2,138)	(2,117)	(1,745)	(1,865)	(3,712)	(3,027)	(2,764)	(2,580)	(3,475)	(2,885)	(2,099)
Income tax	$k	0.0	(607)	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Net income	$k	(1,663)	(1,820)	(1,915)	(1,645)	(1,719)	(2,987)	(2,951)	(2,702)	(2,531)	(2,896)	(2,825)	(1,987)
Diluted EPS	$ per share	(2.56)	not reported	(2.91)	(1.31)	(0.78)	not reported	(0.97)	(0.82)	(0.58)	not reported	(0.28)	(0.12)
Basic EPS	$ per share	(2.56)	not reported	(2.91)	(1.31)	(0.78)	not reported	(0.97)	(0.82)	(0.58)	not reported	(0.28)	(0.12)

Balance sheet

Long-term debt$0, FY2024

Shareholders' equity$6.6m, Q2 FY2026

Soligenix, Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Current assets	$m	11.0	9.5	7.8	9.7	10.3	8.8	7.6	5.3	10.9	8.8	6.6	10.2
Total assets	$m	11.3	9.8	8.1	9.9	10.5	9.0	7.7	5.8	11.3	9.2	6.9	10.5
Current liabilities	$m	5.5	6.2	7.2	6.4	4.5	4.8	not reported	3.6	3.4	3.7	3.6	3.7
Total liabilities	$m	7.1	7.3	7.3	6.4	4.5	4.8	3.8	3.9	3.7	3.9	3.8	3.9
Long-term debt	$m	1.4	1.0	not reported	not reported	not reported	0.0	not reported	not reported	not reported	not reported	not reported	not reported
Shareholders' equity	$m	4.2	2.5	0.8	3.5	5.9	4.1	3.9	1.8	7.6	5.3	3.1	6.6

Cash flow

Operating cash flow−$1.7m, Q2 FY2026

Capital expenditure$2.0k, Q4 FY2025

Soligenix, Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$k	(2,686)	(1,828)	(1,342)	(1,918)	(2,910)	(2,233)	(1,847)	(2,742)	(2,933)	(2,745)	(2,358)	(1,707)
Capital expenditure	$k	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	0.6	2.0	not reported	not reported

Diluted shares (weighted)15.95m, Q2 FY2026

Soligenix, Inc., shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	2.9	2.9	0.5	0.6	0.7	1.3	2.2	3.0	3.3	4.3	10.2	16.0

Shares outstanding: 21.77m at Jul 31, 2026, from the cover of the 10-Q filed Aug 7, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:25 ET. Listed shows no prices and gives no investment advice.